세계의 항바이러스제 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently published an in-depth analysis of the global antiviral drugs market, offering a detailed evaluation of key market dynamics, including drivers, trends, opportunities, and challenges. The report provides exclusive data and statistical insights that highlight the expected growth trajectory of the antiviral drugs market from 2025 to 2032.

Key Insights:

• Antiviral Drugs Market Size (2025E): US$ 75.4 Bn
• Projected Market Value (2032F): US$ 207.9 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 15.60%

Antiviral Drugs Market - Report Scope

Antiviral drugs are pharmaceutical agents designed to treat viral infections by inhibiting virus replication within the host. These drugs are essential in managing diseases such as influenza, HIV, hepatitis, and COVID-19. The increasing prevalence of viral infections, coupled with advancements in drug development, has significantly driven the demand for antiviral therapies. The market caters to hospitals, clinics, research institutions, and pharmaceutical companies, offering a wide range of treatment options. Additionally, the rising adoption of combination therapies and personalized medicine further propels market growth.

Market Growth Drivers

The global antiviral drugs market is expanding due to several key factors, including the rising incidence of viral diseases worldwide. The increasing burden of chronic viral infections such as HIV and hepatitis B & C is fueling demand for effective antiviral treatments. Moreover, the COVID-19 pandemic highlighted the urgent need for antiviral drug development, leading to accelerated research and innovation. Advancements in antiviral drug formulations, including long-acting injectables and nanotechnology-based drug delivery systems, are improving treatment efficacy and patient compliance. Furthermore, government initiatives and funding for antiviral drug research, along with strategic collaborations between pharmaceutical companies, are supporting market expansion.

Market Restraints

Despite its promising growth, the antiviral drugs market faces challenges such as high research and development (R&D) costs and lengthy regulatory approval processes. The emergence of drug-resistant viral strains poses a significant hurdle, necessitating continuous drug modifications and new treatment strategies. Additionally, limited accessibility and affordability of antiviral drugs in low- and middle-income countries restrict market penetration. Side effects and adverse reactions associated with antiviral medications also impact patient adherence and treatment outcomes.

Market Opportunities

The antiviral drugs market presents significant growth opportunities driven by ongoing advancements in biotechnology and drug discovery. The development of broad-spectrum antiviral drugs capable of targeting multiple viruses offers potential for market expansion. Additionally, the increasing adoption of artificial intelligence (AI) and machine learning in drug discovery is accelerating the identification of novel antiviral compounds. The integration of antiviral drugs with immunotherapies and monoclonal antibodies is expected to enhance treatment effectiveness. Expanding healthcare infrastructure in emerging economies, coupled with rising investments in infectious disease research, will further drive market growth.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the antiviral drugs market globally?
• How are regulatory policies influencing the development and approval of antiviral medications?
• What are the emerging trends and technological advancements shaping the market?
• Who are the key players contributing to the market, and what strategies are they employing to maintain their competitive edge?
• What are the future growth opportunities and investment prospects in the global antiviral drugs market?

Competitive Intelligence and Business Strategy

Leading players in the global antiviral drugs market, including Gilead Sciences, GlaxoSmithKline, and Merck & Co., focus on continuous innovation, strategic partnerships, and mergers & acquisitions to strengthen their market position. These companies invest heavily in R&D to develop next-generation antiviral therapies with enhanced efficacy and safety profiles. Collaborations with government agencies, research institutes, and biotech firms are accelerating drug discovery and development processes. Additionally, increased efforts in expanding global distribution networks and improving access to antiviral drugs in underserved regions are expected to drive long-term market growth.

Key Companies Profiled:

• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• AbbVie
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Aurobindo Pharma
• Dr. Reddy's Laboratories Ltd.

Antiviral Drugs Market Segmentation

By Drug Class

• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others

By Type

• Branded
• Generics

By Application

• HIV
• Hepatitis
• Herpes
• Influenza
• Others

By Region

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• The Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Antiviral Drugs Market Snapshot, 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Key Promotional Strategies by Manufacturer
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Antiviral Drugs Outlook, 2019-2032

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
• 4.3. Global Antiviral Drugs Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2024
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
    • 4.3.3.1. DNA Polymerase Inhibitors
    • 4.3.3.2. Reverse Transcriptase Inhibitors
    • 4.3.3.3. Protease Inhibitors
    • 4.3.3.4. Neuraminidase Inhibitors
    • 4.3.3.5. Others
  • 4.3.4. Market Attractiveness Analysis: Drug Class
• 4.4. Global Antiviral Drugs Market Outlook: Type
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019-2024
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
    • 4.4.3.1. Branded
    • 4.4.3.2. Generics
  • 4.4.4. Market Attractiveness Analysis: Type
• 4.5. Global Antiviral Drugs Market Outlook: Application
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 4.5.3.1. HIV
    • 4.5.3.2. Hepatitis
    • 4.5.3.3. Herpes
    • 4.5.3.4. Influenza
    • 4.5.3.5. Others
  • 4.5.4. Market Attractiveness Analysis: Application

5. Global Antiviral Drugs Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Antiviral Drugs Outlook, 2019-2032

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Type
  • 6.2.4. By Application
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
  • 6.4.1. DNA Polymerase Inhibitors
  • 6.4.2. Reverse Transcriptase Inhibitors
  • 6.4.3. Protease Inhibitors
  • 6.4.4. Neuraminidase Inhibitors
  • 6.4.5. Others
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
  • 6.5.1. Branded
  • 6.5.2. Generics
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 6.6.1. HIV
  • 6.6.2. Hepatitis
  • 6.6.3. Herpes
  • 6.6.4. Influenza
  • 6.6.5. Others
• 6.7. Market Attractiveness Analysis

7. Europe Antiviral Drugs Outlook, 2019-2032

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Type
  • 7.2.4. By Application
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
  • 7.4.1. DNA Polymerase Inhibitors
  • 7.4.2. Reverse Transcriptase Inhibitors
  • 7.4.3. Protease Inhibitors
  • 7.4.4. Neuraminidase Inhibitors
  • 7.4.5. Others
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
  • 7.5.1. Branded
  • 7.5.2. Generics
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 7.6.1. HIV
  • 7.6.2. Hepatitis
  • 7.6.3. Herpes
  • 7.6.4. Influenza
  • 7.6.5. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Antiviral Drugs Outlook, 2019-2032

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Type
  • 8.2.4. By Application
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
  • 8.4.1. DNA Polymerase Inhibitors
  • 8.4.2. Reverse Transcriptase Inhibitors
  • 8.4.3. Protease Inhibitors
  • 8.4.4. Neuraminidase Inhibitors
  • 8.4.5. Others
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
  • 8.5.1. Branded
  • 8.5.2. Generics
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 8.6.1. HIV
  • 8.6.2. Hepatitis
  • 8.6.3. Herpes
  • 8.6.4. Influenza
  • 8.6.5. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Antiviral Drugs Outlook, 2019-2032

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Type
  • 9.2.4. By Application
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
  • 9.4.1. DNA Polymerase Inhibitors
  • 9.4.2. Reverse Transcriptase Inhibitors
  • 9.4.3. Protease Inhibitors
  • 9.4.4. Neuraminidase Inhibitors
  • 9.4.5. Others
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
  • 9.5.1. Branded
  • 9.5.2. Generics
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 9.6.1. HIV
  • 9.6.2. Hepatitis
  • 9.6.3. Herpes
  • 9.6.4. Influenza
  • 9.6.5. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Antiviral Drugs Outlook, 2019-2032

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Type
  • 10.2.4. By Application
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
  • 10.4.1. DNA Polymerase Inhibitors
  • 10.4.2. Reverse Transcriptase Inhibitors
  • 10.4.3. Protease Inhibitors
  • 10.4.4. Neuraminidase Inhibitors
  • 10.4.5. Others
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
  • 10.5.1. Branded
  • 10.5.2. Generics
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 10.6.1. HIV
  • 10.6.2. Hepatitis
  • 10.6.3. Herpes
  • 10.6.4. Influenza
  • 10.6.5. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Antiviral Drugs Outlook, 2019-2032

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Type
  • 11.2.4. By Application
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
  • 11.4.1. DNA Polymerase Inhibitors
  • 11.4.2. Reverse Transcriptase Inhibitors
  • 11.4.3. Protease Inhibitors
  • 11.4.4. Neuraminidase Inhibitors
  • 11.4.5. Others
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
  • 11.5.1. Branded
  • 11.5.2. Generics
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 11.6.1. HIV
  • 11.6.2. Hepatitis
  • 11.6.3. Herpes
  • 11.6.4. Influenza
  • 11.6.5. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. F. Hoffmann-La Roche Ltd.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. GlaxoSmithKline plc
  • 12.3.3. AbbVie
  • 12.3.4. Merck & Co., Inc.
  • 12.3.5. Johnson & Johnson Services, Inc.
  • 12.3.6. Bristol-Myers Squibb Company
  • 12.3.7. Cipla Inc.
  • 12.3.8. Aurobindo Pharma
  • 12.3.9. Dr. Reddy's Laboratories Ltd.

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations